Merck seeks ridaforolimus marketing approval from EMA
Ridaforolimus is an investigational mTOR inhibitor being developed by Merck that has completed a Phase 3 clinical trial in patients with soft-tissue and bone sarcomas and is being
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.